Deal alert: MGC Pharmaceuticals Ltd

PKF supports admission to the Main Market of the London Stock Exchange

read timeRead time: 1 min
We are delighted to have supported MGC Pharmaceuticals Ltd on their admission to the main market of the London Stock Exchange, following a strongly supported £6.5 million share placing led by leading UK institutional fund managers, and supported by UK family office and professional high net worth investors.

MGC Pharma is a European based and Australian listed bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines. MGC Pharma is set to become the first medicinal cannabis related company to be admitted to the main market of the London Stock Exchange through a standard listing.

“Listing on the LSE for us has been the culmination of over 24 months hard work, and a vital step in the next stage of growth for MGC Pharma. The support that PKF provided to us throughout the process was invaluable, and has enabled us to make our ambition a reality.”
Roby Zomer, Co-Founder, Managing Director and CEO | MGC Pharmaceuticals Ltd
PKF acted as reporting accountant on the transaction and the Capital Markets team included Dominic Roberts, Adam Humphreys and Lauren Haslam.

Find out more about how our Capital Markets team can support you and your business here.